All Stories
Follow
Subscribe to eleva GmbH

eleva GmbH

Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins

Freiburg (ots)

Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates.

Its recently expanded production capacity enables Eleva to conduct clinical studies of its drug candidates. Among the first ones is factor H which will be developed through phase II. Up to 2,500 l will be produced in state-of-the-art single-use reactors at a GMP site.

Eleva’s moss-based platform offers unique advantages for recombinant protein development, such as:

  • Moss glycostructure naturally lacks core α-1,6 fucose – a known allergen – while any other glycans can be “humanized”. This leads to excellent organ uptake.
  • Being a plant, it will not be contaminated with animal pathogens, which eliminates the need for antibiotics.
  • The moss production system, haploid by nature, is based on an intact organism, not on cell cultures. This guarantees exceptionally stable modifications.

Eleva is leveraging those advantages to produce complex proteins for future therapies, such as 2nd generation oncological therapeutics, or virus-like-particles (VLP) for vaccine development.

Ralf Smit, CBO of Eleva: “With production scaling up, we can now offer to develop difficult-to-express therapeutic proteins in collaboration with partners in the pharmaceutical industry. We look forward to our moss platform unlocking the very promising potential of complex candidates for the benefit of patients.”

About Eleva

Based in Freiburg, Germany, Eleva develops novel biological therapies with its pharmaceutical partners. The privately-held company leverages its unique moss-based production platform to produce supreme biologics like antibodies, replacement enzymes, or fusion toxins. Eleva has successfully developed drug candidates into clinical phases.

Contact:

eleva GmbH
Fabienne Zeitter
pr@elevabiologics.com
Phone: +49 761 470 990
www.elevabiologics.com

Original content of: eleva GmbH, transmitted by news aktuell

More stories: eleva GmbH
More stories: eleva GmbH
  • 14.09.2021 – 10:30

    Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H

    Freiburg (ots) - Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases. Eleva has ordered four more state-of-the-art, 500 l single-use reactors from Sartorius Stedim Systems. The scale-up will enable Eleva to enter ...

  • 06.01.2021 – 10:00

    Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member

    Freiburg (ots) - Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to ...

  • 03.06.2020 – 10:00

    Eleva's drug candidate to be examined for use in Covid-19 treatment

    Freiburg (ots) - Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through ...